Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centersAndrew M. Evens, Matthew A. Lunning, Alexey V. Danilov et al.|Blood|2021Cited by 125
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysisJuan Pablo Alderuccio, Tatyana Feldman, Adam J. Olszewski et al.|Blood Advances|2021Cited by 54
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort studyAdam Zayac, Matthew A. Lunning, Andrew M. Evens et al.|Haematologica|2021Cited by 44
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapyDavid A. Bond, Jonathon B. Cohen, Jeffrey M. Switchenko et al.|Blood Advances|2021Cited by 41
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current eraAnand Patel, Olatoyosi Odenike, James Yoon et al.|Blood Advances|2024Cited by 32